Business / Finance

RSS

USPI fourth quarter consolidated net revenues increase 5% to $162.0M

United Surgical Partners International, Inc. today announced results for the fourth quarter and year ended December 31, 2011.

1 Mar 2012

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 28 February 2012 to review the Group's results for 2011, published today.

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

GI Dynamics reports revenues of US$234,000 for year ended 31 December 2011

GI Dynamics, Inc., a company pioneering the development of effective, non-surgical approaches for treating type 2 diabetes and obesity, is pleased to provide its financial results for the year ended 31 December 2011.

28 Feb 2012

ICON announces acquisition of PriceSpective

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of PriceSpective LLC, a global leader in value strategy consulting.

28 Feb 2012

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

Shanghai ShowStar, UBM Asia form JV company

UBM Asia announces that it has formed a JV company, Shanghai UBM ShowStar Exhibition Co Ltd with Shanghai ShowStar Exhibition Service Co Ltd, owner of China International Exhibition & Symposium on Dental Equipment, Technology & Products.

28 Feb 2012

Simpler Consulting forms new entity in India

Simpler Consulting, L.P., a leading global management consulting firm, today announced the formation of a new entity, Simpler Consulting India to expand the Company's geographic footprint to bring Lean management services to healthcare and manufacturing organizations in India.

28 Feb 2012

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Samsung Biologics and Biogen Idec announced today that the companies have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars in keeping with their agreement announced in December.

28 Feb 2012

St. Jude Medical quarterly dvidend increases to $0.92 per share

St. Jude Medical, Inc., a global medical device company, today announced that its Board of Directors declared a 10 percent increase in the company's quarterly dividend to $0.23 per common share. At the new rate, the annual dividend would be $0.92 per share, compared to the previous annual dividend of $0.84 per share.

27 Feb 2012

Materion fourth quarter sales down 6% to $334.4M

Materion Corporation today reported fourth quarter and full-year 2011 results. The Company also confirmed its outlook for a stronger 2012. The results for the quarter and the outlook are consistent with those announced on February 8, 2012.

27 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Dendreon 2011 product revenue increases to $213.5M

Dendreon Corporation today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

27 Feb 2012

Savient fourth quarter net loss increases to $30.9 million

Savient Pharmaceuticals, Inc. reported financial results for the three months ended December 31, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA(pegloticase). Savient ended the quarter with approximately $170 million in cash and short-term investments, a decrease of $33 million for the quarter.

27 Feb 2012

New research report on the electrosurgical devices market

ReportsnReports adds new market research report 'Electrosurgical Devices Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018' to its store. The global electrosurgical devices market is expected to reach $1,412.8m by 2018 growing at a CAGR of 5%.

27 Feb 2012